Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: Systems pharmacology approach

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 10, 2014, Pages

  Sharan, S ^a   Woo, S ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; N DEETHYLSUNITINIB; PLACENTAL GROWTH FACTOR; SUNITINIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; HOST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMULATION; TREATMENT RESPONSE; TUMOR CELL;

EID: 84926498218     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.36     Document Type: Article

References (50)

1. Murukesh, N., Dive, C. & Jayson, G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102, 8-18 (2010).
2. Sessa, C., Guibal, A., Del Conte, G. & Rüegg, C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol. 5, 378-391 (2008).
3. Jahangiri, A. & Aghi, M.K. Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Biochim. Biophys. Acta 1825, 86-100 (2012).
4. Jain, R.K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009).
5. Duda, D.G., Munn, L.L. & Jain, R.K. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J. Natl. Cancer Inst. 105, 762-765 (2013).
6. Ebos, J.M., Lee, C.R., Christensen, J.G., Mutsaers, A.J. & Kerbel, R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor effcacy. Proc. Natl. Acad. Sci. U.S.A. 104, 17069-17074 (2007). Copyright (2007) National Academy of Sciences, U.S.A.
7. Lindauer, A. et al. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin. Pharmacol. Ther. 87, 601-608 (2010).
8. Vicini, P. & van der Graaf, P.H. Systems pharmacology for drug discovery and development: paradigm shift or fash in the pan? Clin. Pharmacol. Ther. 93, 379-381 (2013).
9. van der Graaf, P.H. & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460-1464 (2011).
10. Kontovinis, L.F., Papazisis, K.T., Touplikioti, P. , Andreadis, C., Mouratidou, D. & Kortsaris, A.H. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9, 82 (2009).
11. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
12. Cook, K.M. & Figg, W.D. Angiogenesis inhibitors: current strategies and future prospects. CA. Cancer J. Clin. 60, 222-243 (2010).
13. Wagner, J.P. et al. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Sci. Signal. 6, ra58 (2013).
14. Kirouac, D.C. et al. Computational modeling of ERBB2-amplifed breast cancer identifes combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 6, ra68 (2013).
15. Rudge, J.S. et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting effcacious angiogenic blockade. Proc. Natl. Acad. Sci. U.S.A. 104, 18363-18370 (2007).
16. Bertolini, F. , Shaked, Y. , Mancuso, P. & Kerbel, R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identifcation. Nat. Rev. Cancer 6, 835-845 (2006).
17. Manenti, L. et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol. Cancer Ther. 4, 715-725 (2005).
18. Yuasa, T. , Takahashi, S., Hatake, K., Yonese, J. & Fukui, I. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci. 102, 1949-1957 (2011).
19. Hori, S.S. & Gambhir, S.S. Mathematical model identifes blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 3, 109ra116 (2011).
20. Klümpen, H.J., Samer, C.F., Mathijssen, R.H., Schellens, J.H. & Gurney, H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat. Rev. 37, 251-260 (2011).
21. Hansson, E.K. et al. PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST. CPT. Pharmacometrics Syst. Pharmacol. 2, e84 (2013).
22. Gavin, T.P., Robinson, C.B., Yeager, R.C., England, J.A., Nifong, L.W. & Hickner, R.C. Angiogenic growth factor response to acute systemic exercise in human skeletal muscle. J. Appl. Physiol. 96, 19-24 (2004).
23. Mouawad, R., Spano, J.P., Comperat, E., Capron, F. & Khayat, D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur. J. Cancer 45, 1407-1414 (2009).
24. Harmon, C.S. et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J. Transl. Med. 9, 120 (2011).
25. Deprimo, S.E. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 5, 32 (2007).
26. Llovet, J.M., Peña, C.E., Lathia, C.D., Shan, M., Meinhardt, G. & Bruix, J.; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18, 2290-2300 (2012).
27. Escudier, B. et al. Sorafenib for treatment of renal cell carcinoma: Final effcacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009).
28. Jürgensmeier, J.M. et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br. J. Cancer 108, 1316-1323 (2013).
29. Rini, B.I. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26, 3743-3748 (2008).
30. Goel, S., Wong, A.H. & Jain, R.K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb. Perspect. Med. 2, a006486 (2012).
31. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
32. Finley, S.D. & Popel, A.S. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J. Natl. Cancer Inst. 105, 802-811 (2013).
33. Tugues, S., Koch, S., Gualandi, L., Li, X. & Claesson-Welsh, L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol. Aspects Med. 32, 88-111 (2011).
34. Tan, W.H., Popel, A.S. & Mac Gabhann, F. Computational model of VEGFR2 pathway to ERK activation and modulation through receptor traffcking. Cell. Signal. 25, 2496-2510 (2013).
35. Hoeben, A., Landuyt, B., Highley, M.S., Wildiers, H., Van Oosterom, A.T. & De Bruijn, E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56, 549-580 (2004).
36. Soker, S., Miao, H.Q., Nomi, M., Takashima, S. & Klagsbrun, M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85, 357-368 (2002).
37. Sawano, A., Takahashi, T., Yamaguchi, S., Aonuma, M. & Shibuya, M. Flt-1 but not KDR/ Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 7, 213-221 (1996).
38. Shibuya, M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer 2, 1097-1105 (2011).
39. Papadopoulos, N. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171-185 (2012).
40. Finley, S.D., Dhar, M. & Popel, A.S. Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front. Oncol. 3, 196 (2013).
41. Stefanini, M.O., Wu, F.T., Mac Gabhann, F. & Popel, A.S. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res. 70, 9886-9894 (2010).
42. Zhang, X.Y., Birtwistle, M.R. & Gallo, J.M. A General Network Pharmacodynamic ModelBased Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway. CPT. Pharmacometrics Syst. Pharmacol. 3, e92 (2014).
43. Agoram, B. Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models. CPT. Pharmacometrics Syst. Pharmacol. 3, e101 (2014).
44. D'Argenio, D.Z., Schumitzky, A. & Wang, X. ADAPT 5 User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software (Biomedical Simulations Resource, Los Angeles, 2009).
45. Speed, B. et al. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab. Dispos. 40, 539-555 (2012).
46. Houk, B.E., Bello, C.L., Kang, D. & Amantea, M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15, 2497-2506 (2009).
47. Mager, D.E. & Jusko, W.J. Pharmacodynamic modeling of time-dependent transduction systems. Clin. Pharmacol. Ther. 70, 210-216 (2001).
48. Rocchetti, M. et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. Cancer Chemother. Pharmacol. 71, 1147-1157 (2013).
49. Simeoni, M. et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 64, 1094-1101 (2004).
50. Eisenhauer, E.A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).